Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP

Susan H Eshleman; Donald R Hoover; Shu Chen; Sarah E Hudelson; Laura A Guay; Anthony Mwatha; Susan A Fiscus; Francis Mmiro; Philippa Musoke; J. Brooks Jackson; Newton Kumwenda; Taha Taha

doi:10.1086/430764

Back

Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP

Journal article

Open access

Peer reviewed

Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP

Susan H Eshleman, Donald R Hoover, Shu Chen, Sarah E Hudelson, Laura A Guay, Anthony Mwatha, Susan A Fiscus, Francis Mmiro, Philippa Musoke, J. Brooks Jackson, …

The Journal of infectious diseases, Vol.192(1), pp.30-36

07/01/2005

DOI: 10.1086/430764

PMID: 15942891

Files and links (1)

url

https://doi.org/10.1086/430764View

Published (Version of record) Open Access

Abstract

ObjectiveIn the Human Immunodeficiency Virus (HIV) Network for Prevention Trials (HIVNET) 012 trial in Uganda, 6-8 weeks after single-dose nevirapine (SD-NVP), NVP resistance mutations were detected at a higher rate in women with HIV-1 subtype D than in women with subtype A. Here, we evaluate the rate of NVP resistance mutations in women with subtype C MethodsNVP resistance mutations were detected using the ViroSeq HIV-1 Genotyping System ResultsThe portion of women with any NVP resistance mutation was higher in those with subtype C (45/65 [69.2%] in the NVP and zidovudine trial, Malawi) than in those in the HIVNET 012 trial with either subtype A (28/144 [19.4%]; P<.0001) or subtype D (35/97 [36.1%]; P<.0001). In a multivariate model, subtype (C vs. A: odds ratio [OR], 8.73 [95% confidence interval {CI}, 4.29-17.76]; C vs. D: OR, 3.38 [95% CI, 1.65-6.93]) and viral load at delivery (OR, 2.35 [95% CI, 1.62-3.40]) independently predicted NVP resistance mutations, but maternal age, parity, and time between SD-NVP and the 6-8-week visit did not ConclusionsThe rate of NVP resistance mutations after SD-NVP was significantly higher in women with HIV-1 subtype C than in women with subtype A or D. Studies are needed to assess the clinical significance of this finding

Details

Title: Subtitle: Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP
Creators: Susan H Eshleman - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Donald R Hoover - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Shu Chen - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Sarah E Hudelson - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Laura A Guay - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Anthony Mwatha - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Susan A Fiscus - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Francis Mmiro - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Philippa Musoke - 1Department of Pathology, Johns Hopkins Medical Institutions, and
J. Brooks Jackson - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Newton Kumwenda - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Taha Taha - 1Department of Pathology, Johns Hopkins Medical Institutions, and
Resource Type: Journal article
Publication Details: The Journal of infectious diseases, Vol.192(1), pp.30-36
DOI: 10.1086/430764
PMID: 15942891
NLM abbreviation: J Infect Dis
ISSN: 0022-1899
eISSN: 1537-6613
Publisher: The University of Chicago Press
Language: English
Date published: 07/01/2005
Academic Unit: Pathology; VPMA - Administration
Record Identifier: 9984047735702771

Metrics

12 Record Views

125 Times Cited - Web of Science